Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

70.50 -0.55 (-0.77%)
Streaming Delayed Price Updated: 10:23 AM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 188,315
Open 71.33
Bid (Size) 70.50 (2)
Ask (Size) 70.60 (7)
Prev. Close 71.05
Today's Range 70.25 - 71.40
52wk Range 50.35 - 83.95
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga

Performance

YTD
+7.72%
+7.72%
1 Month
+8.01%
+8.01%
3 Month
+9.90%
+9.90%
6 Month
+21.13%
+21.13%
1 Year
+32.44%
+32.44%

More News

Read More
Nasdaq Reverses Losses Amid Nvidia Fanfare
Via Talk Markets
Gold Moves Higher; Medtronic Posts Upbeat Results
Via Benzinga
Stocks Move Higher, Walmart Hits Record High, Natural Gas Reaches 5-Month Peak: What's Driving Markets Tuesday?
Via Benzinga
Topics Energy
Exposures Fossil Fuels
Cracking The Code: Understanding Analyst Reviews For Incyte
Via Benzinga
Incyte Breaks Out To 17-Month High As Jakafi Demand Surges
Via Investor's Business Daily
What's Going On With Incyte Shares Tuesday?
Via Benzinga
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
Via Benzinga
Nasdaq Gains 100 Points; Lowe's Earnings Beat Views
Via Benzinga
Topics Earnings
Exposures Financial
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
Via Investor's Business Daily
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
This Alphabet Analyst Turns Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
Via Benzinga
Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.